- Meeting abstract
- Open Access
Three-year outcomes with left ventricular assist devices in country with restricted heart transplantation
© Medressova et al. 2015
- Published: 16 December 2015
- Heart Transplantation
- Left Ventricular Assist Device
- Advanced Heart Failure
- Cumulative Survival Rate
- Destination Therapy
As a consequence of limited donor availability, there has been a growing interest for alternative strategies, such as left ventricular assist devices (LVAD) as either a bridge to transplantation (BTT) or as destination therapy (DT) for the treatment of the advanced heart failure. The heart transplant program in Kazakhstan is in a nascent stage and therefore patients that are determined to be BTT are expected to have an extended duration of LVAD support.
The objective of this study was to determine outcomes of patients with left ventricular assist devices in country with restricted transplantation.
We analyzed outcomes for 135 patients between November 2011 and November 2014 (mean age=50,5 ± 13,5 years old; Heart Mate II=95 (70,4%), HeartWare=40 (29,6%)). The median duration of support is 474 ± 329,4 days.
In 75 patients (55,6%) the LVAD is used as a BTT and in 60 (44,4%) as a DT, but only 3 of 135 LVAD patients were transplanted. Before 30 days after implantation of LVAD right ventricular failure (n = 20, 14,8%), renal failure (n = 19, 14,1%) and bleeding (requiring reoperation = 10, 7,4%, requiring transfusion of packed red blood cells ≥4U = 23, 17,04%) were the most common adverse events. After 30 days driveline infections (n = 46, 34,1%) and strokes (n = 33, 24,44%) were the most common complications. Cumulative survival rates at 1, 6 months, 1, 2 and 3 years after LVAD implantation is 93%, 86%, 77%, 62% and 51% accordingly. Older age and more acute INTERMACS profiles were related to reduced survival.
The Center's experience shows that LVADs can be implanted as an alternative to heart transplantation with the outcomes that are comparable to those in existing world centers of excellence.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.